НовостиBenzingaNexentis Technologies' MitoCareX Bio Subsidiary Completes Initial Computational Screening Stage Under Its Drug-Discovery Initiative With Boltz Nexentis Technologies' MitoCareX Bio Subsidiary Completes Initial Computational Screening Stage Under Its Drug-Discovery Initiative With Boltz Benzinga 2026.10.26 12:18 (GMT+0) Открыть на Benzinga Другие новости